164 related articles for article (PubMed ID: 8655729)
1. CD7-positive Sézary syndrome with a Th1 cytokine profile.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):368-74. PubMed ID: 8655729
[TBL] [Abstract][Full Text] [Related]
2. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).
Vonderheid EC; Bigler RD; Kotecha A; Boselli CM; Lessin SR; Bernengo MG; Polansky M
J Invest Dermatol; 2001 Sep; 117(3):654-62. PubMed ID: 11564173
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous IL-8 production by CD4(+), CD7(+) leukemia cells in erythrodermic Sézary syndrome.
Ogawa F; Shimizu K; Hamasakia Y; Tanaka Y; Katayama I; Yamada Y; Tomonaga M
Leuk Lymphoma; 2002 May; 43(5):1061-6. PubMed ID: 12148887
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic identification of Sezary cells in peripheral blood.
Bogen SA; Pelley D; Charif M; McCusker M; Koh H; Foss F; Garifallou M; Arkin C; Zucker-Franklin D
Am J Clin Pathol; 1996 Dec; 106(6):739-48. PubMed ID: 8980349
[TBL] [Abstract][Full Text] [Related]
5. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
[TBL] [Abstract][Full Text] [Related]
6. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens.
Tokura Y; Yagi H; Ohshima A; Kurokawa S; Wakita H; Yokote R; Shirahama S; Furukawa F; Takigawa M
Br J Dermatol; 1995 Jul; 133(1):6-12. PubMed ID: 7669641
[TBL] [Abstract][Full Text] [Related]
8. Expression of V beta gene segments by Sezary cells.
Gorochov G; Bachelez H; Cayuela JM; Legac E; Laroche L; Dubertret L; Sigaux F
J Invest Dermatol; 1995 Jul; 105(1):56-61. PubMed ID: 7542297
[TBL] [Abstract][Full Text] [Related]
9. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-7 is a growth factor for Sézary lymphoma cells.
Dalloul A; Laroche L; Bagot M; Mossalayi MD; Fourcade C; Thacker DJ; Hogge DE; Merle-Béral H; Debré P; Schmitt C
J Clin Invest; 1992 Sep; 90(3):1054-60. PubMed ID: 1381718
[TBL] [Abstract][Full Text] [Related]
11. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.
Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M
Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208
[TBL] [Abstract][Full Text] [Related]
12. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
15. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.
Rappl G; Muche JM; Abken H; Sterry W; Tilgen W; Ugurel S; Reinhold U
J Am Acad Dermatol; 2001 Mar; 44(3):456-61. PubMed ID: 11209115
[TBL] [Abstract][Full Text] [Related]
16. Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sézary syndrome.
Dummer R; Nestle FO; Niederer E; Ludwig E; Laine E; Grundmann H; Grob P; Burg G
Arch Dermatol Res; 1999 Jun; 291(6):307-11. PubMed ID: 10421055
[TBL] [Abstract][Full Text] [Related]
17. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of genetically defined tumor cells in CD7 as well as CD26 positive and negative circulating T-cell subsets in Sézary syndrome.
Steinhoff M; Schöpp S; Assaf C; Muche M; Beyer M; Sterry W; Lukowsky A
Leuk Res; 2009 Jan; 33(1):88-99. PubMed ID: 18672285
[TBL] [Abstract][Full Text] [Related]
19. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1).
Dummer R; Geertsen R; Ludwig E; Niederer E; Burg G
Leuk Lymphoma; 1998 Feb; 28(5-6):515-22. PubMed ID: 9613981
[TBL] [Abstract][Full Text] [Related]
20. CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death.
Rappl G; Abken H; Muche JM; Sterry W; Tilgen W; André S; Kaltner H; Ugurel S; Gabius HJ; Reinhold U
Leukemia; 2002 May; 16(5):840-5. PubMed ID: 11986945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
